Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis

Impact of pneumococcal vaccination in children on serotype distribution in adult community-acquired pneumonia using the serotype-specific multiplex urinary antigen detection assay

(2016) Mathias W. Pletz et al.   VACCINE

Corrigendum to “The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50years of age and older: A systematic review and meta-analysis” [Vaccine 34 (2016) 1540–1550]

(2016) Hannah Kraicer-Melamed et al.   VACCINE

The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50 years of age and older: A systematic review and meta-analysis

(2016) Hannah Kraicer-Melamed et al.   VACCINE

Efficacy of 23-valent pneumococcal polysaccharide vaccine in preventing community-acquired pneumonia among immunocompetent adults: A systematic review and meta-analysis of randomized trials

(2016) Wen-qi Diao et al.   VACCINE

Efficacy of PPV23 in Preventing Pneumococcal Pneumonia in Adults at Increased Risk – A Systematic Review and Meta-Analysis

(2016) Julia Schiffner-Rohe et al.   PLoS One

Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against Invasive Disease and Hospital-Treated Pneumonia Among People Aged ≥65 Years: A Retrospective Case-Control Study

(2015) Maya Leventer-Roberts et al.   CLINICAL INFECTIOUS DISEASES

Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia

(2015) Chamira Rodrigo et al.   EUROPEAN RESPIRATORY JOURNAL

Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance

(2015) Matthew R Moore et al.   LANCET INFECTIOUS DISEASES

Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults

(2015) Marc J.M. Bonten et al.   NEW ENGLAND JOURNAL OF MEDICINE

The 23-valent pneumococcal polysaccharide vaccine is effective in elderly adults over 75 years old—Taiwan's PPV vaccination program

(2015) Ying-Huang Tsai et al.   VACCINE

Effects of Infant Pneumococcal Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany

(2015) Mark van der Linden et al.   PLoS One

Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine Against Community-Acquired Pneumonia in the General Population Aged >=60 Years: 3 Years of Follow-up in the CAPAMIS Study

(2014) O. Ochoa-Gondar et al.   CLINICAL INFECTIOUS DISEASES

Impact of 13-Valent Pneumococcal Conjugate Vaccination in Invasive Pneumococcal Disease Incidence and Mortality

(2014) Zitta Barrella Harboe et al.   CLINICAL INFECTIOUS DISEASES

Effectiveness of 23-valent pneumococcal polysaccharide vaccine in adults aged 60 years and over in the Region of Madrid, Spain, 2008–2011

(2014) M A Gutiérrez Rodríguez et al.   Eurosurveillance

Age-related immune response to pneumococcal polysaccharide vaccination: lessons for the clinic

(2014) Anita S Iyer et al.   Expert Review of Vaccines

The effectiveness of the polysaccharide pneumococcal vaccine for the prevention of hospitalizations due to Streptococcus pneumoniae community-acquired pneumonia in the elderly differs between the sexes: Results from the Community-Acquired Pneumonia Organization (CAPO) international cohort study

(2014) Timothy L. Wiemken et al.   VACCINE

The stubborn persistence of adult pneumococcal pneumonia as a public health problem

(2014) Rosalind Hollingsworth et al.   Human Vaccines & Immunotherapeutics

Preventing non bacteremic pneumococcal pneumonia in older adults

(2014) David S Fedson   Human Vaccines & Immunotherapeutics

Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995–2011

(2013) Wallis Rudnick et al.   VACCINE

Validation of an Immunodiagnostic Assay for Detection of 13 Streptococcus pneumoniae Serotype-Specific Polysaccharides in Human Urine

(2012) Michael W. Pride et al.   Clinical and Vaccine Immunology

The role of Streptococcus pneumoniae in community-acquired pneumonia among adults in Europe: a meta-analysis

(2012) M. H. Rozenbaum et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

GRADE guidelines: 13. Preparing Summary of Findings tables and evidence profiles—continuous outcomes

(2012) Gordon H. Guyatt et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Clinical effectiveness of pneumococcal polysaccharide vaccine in men: California Men's Health Study

(2012) Rulin C. Hechter et al.   VACCINE

Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales

(2012) Nick J. Andrews et al.   VACCINE

Community-acquired pneumonia in younger patients is an entity on its own

(2011) Benjamin Klapdor et al.   EUROPEAN RESPIRATORY JOURNAL

GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables

(2011) Gordon Guyatt et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Development of a sensitive, multiplexed immunoassay using xMAP beads for detection of serotype-specific Streptococcus pneumoniae antigen in urine samples

(2010) C. L. Sheppard et al.   JOURNAL OF MEDICAL MICROBIOLOGY

New strategies are needed to improve the accuracy of influenza vaccine effectiveness estimates among seniors

(2009) Jennifer Clark Nelson et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: A matched case–control study

(2009) Angel Vila-Corcoles et al.   VACCINE

Pneumococcal Serotypes and Mortality following Invasive Pneumococcal Disease: A Population-Based Cohort Study

(2009) Zitta B. Harboe et al.   PLOS MEDICINE

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE